October 18, 2004
Chronic Disease Mangement
Joanne Alder, David Mirkin, and Rob Parke examine some ways of assessing the cost-effectiveness of disease management programmes and draw some conclusions from the US experience.
In the US system, a major criterion for DM programmes is that they have the potential to demonstrate financial savings for the ultimate healthcare payers, whether that be insurers, employers, or the state. Savings are based on a simple principle: if the savings from decreased use of medical care are greater than the costs of running the programme, the programme has generated a positive return on investment (ROI).
Posted by Tom Troceen